Entry inhibitors are emerging as an attractive class of therapeutics for hepatitis C virus (HCV) infection. Entry inhibitors target either virion-associated factors or cellular factors necessary for infection. By blocking entry into cells, entry inhibitors prevent both the establishment of persistent reservoirs and the emergence of resistant variants during viral replication. Furthermore, entry inhibitors protect naïve cells from virus-induced alterations. Combining entry inhibitors with direct-acting antivirals (DAAs) may therefore improve treatment outcomes, particularly in the context of organ transplantation. The role of DAAs in transplantation, while still under clinical investigation, carries the risk of recipient infection and HCV-induced disease, since DAAs act only after infection is established. Thus, entry inhibitors provide a perspective to improve patient outcomes during organ transplantation. Applying this approach for transplant of organs from HCV-positive donors to HCV-negative recipients may also contribute to alleviate the medical burden of organ shortage.

中文翻译：

---

进入抑制剂：预防器官移植中丙型肝炎病毒感染的观点

进入抑制剂正在成为丙型肝炎病毒 (HCV) 感染的一类有吸引力的治疗剂。进入抑制剂靶向病毒相关因子或感染所需的细胞因子。通过阻止进入细胞，进入抑制剂可以防止病毒复制过程中持久性储存库的建立和抗性变体的出现。此外，进入抑制剂保护幼稚细胞免受病毒诱导的改变。因此，将进入抑制剂与直接作用抗病毒药物 (DAA) 相结合可能会改善治疗结果，特别是在器官移植的情况下。DAA 在移植中的作用虽然仍在临床研究中，但存在受者感染和 HCV 诱发疾病的风险，因为 DAA 仅在感染确定后才起作用。因此，进入抑制剂提供了改善器官移植期间患者预后的前景。将这种方法用于将 HCV 阳性供体的器官移植到 HCV 阴性受体也可能有助于减轻器官短缺的医疗负担。